Pretreatment with hyperoxia reduces in vivo infarct size and cell death by apoptosis with an early and delayed phase of protection

European Journal of Cardio-thoracic Surgery

Volumn 39, Issue 2, 2011, Pages 233-240

  Foadoddini, Mohsen ^a,c   Esmailidehaj, Mansour ^b   Mehrani, Hosein ^c   Sadraei, Seid Homayoon ^c   Golmanesh, Leila ^c   Wahhabaghai, Hannaneh ^d   Valen, Guro ^e   Khoshbaten, Ali ^c  

^a BIRJAND UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID SADOUGHI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e UNIVERSITY OF OSLO   (Norway)

Author keywords

Apoptosis; Bax; Bcl 2; Infarct size; Normobaric hyperoxia; Reperfusion

Indexed keywords

CASPASE 3; DNA; PROTEIN BAX; PROTEIN BCL 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL DEATH; CONTROLLED STUDY; DNA FRAGMENTATION; ENZYME ACTIVITY; HEART ARRHYTHMIA; HEART HEMODYNAMICS; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HYPEROXIA; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REPERFUSION INJURY;

ANIMALS; APOPTOSIS; ARRHYTHMIAS, CARDIAC; BCL-2-ASSOCIATED X PROTEIN; BLOOD PRESSURE; CASPASE 3; DNA FRAGMENTATION; HEART RATE; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MALE; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; OXYGEN; OXYGEN INHALATION THERAPY; PARTIAL PRESSURE; PROTO-ONCOGENE PROTEINS C-BCL-2; RATS; RATS, WISTAR; TIME FACTORS;

EID: 78751579230     PISSN: 10107940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcts.2010.05.036     Document Type: Article

References (25)

1. Valen G., Vaage J. Pre- and postconditioning during cardiac surgery. Basic Res Cardiol 2005, 100:179-186.
2. Choi H., Kim S.H., Chun Y.S., Cho Y.S., Park J.W., Kim M.S. In vivo hyperoxic preconditioning prevents myocardial infarction by expressing Bcl-2. Exp Biol Med (Maywood) 2006, 231:463-472.
3. Ruusalepp A., Czibik G., Flatebo T., Vaage J., Valen G. Myocardial protection evoked by hyperoxic exposure involves signaling through nitric oxide and mitogen activated protein kinases. Basic Res Cardiol 2007, 102:318-326.
4. Tahepold P., Valen G., Starkopf J., Kairane C., Zilmer M., Vaage J. Pretreating rats with hyperoxia attenuates ischemia-reperfusion injury of the heart. Life Sci 2001, 68:1629-1640.
5. Bigdeli M.R., Hajizadeh S., Froozandeh M., Rasulian B., Heidarianpour A., Khoshbaten A. Prolonged and intermittent normobaric hyperoxia induce different degrees of ischemic tolerance in rat brain tissue. Brain Res 2007, 1152:228-233.
6. Wahhabaghai H., Rasoulian B., Esmaili M., Mehrani H.A., Mohammadhosseniakbari H., Mofid M., Jafari M., Noroozi M., Foadoddini M., Asgai A., Khoshbaten A. Hyperoxia-induced protection against rat's renal ischemic damage: relation to oxygen exposure time. Ren Fail 2009, 31:514-521.
7. Esmaili D.M., Baharvand B., Rasoulian B., Foadaddini M., Asgari A., Noroozzadeh A., Poorkhalili K., Wahhab A.H., Khoshbaten A. Delayed protective effects of hyperoxia against cardiac arrhythmias and infarction in anesthetized rats. J Surg Res 2009, 151:55-61.
8. Labruto F., Yang J., Vaage J., Valen G. Role of tumor necrosis factor alpha and its receptor I in preconditioning by hyperoxia. Basic Res Cardiol 2005, 100:198-207.
9. Tahepold P., Vaage J., Starkopf J., Valen G. Hyperoxia elicits myocardial protection through a nuclear factor kappaB-dependent mechanism in the rat heart. J Thorac Cardiovasc Surg 2003, 125:650-660.
10. Eefting F., Rensing B., Wigman J., Pannekoek W.J., Liu W.M., Cramer M.J., Lips D.J., Doevendans P.A. Role of apoptosis in reperfusion injury. Cardiovasc Res 2004, 61:414-426.
11. Kitsis R.N., Mann D.L. Apoptosis and the heart: a decade of progress. J Mol Cell Cardiol 2005, 38:1-2.
12. Zhao Z.Q., Velez D.A., Wang N.P., Hewan-Lowe K.O., Nakamura M., Guyton R.A., Vinten-Johansen J. Progressively developed myocardial apoptotic cell death during late phase of reperfusion. Apoptosis 2001, 6:279-290.
13. Zhao Z.Q., Morris C.D., Budde J.M., Wang N.P., Muraki S., Sun F.Y., Guyton R.A. Inhibition of myocardial apoptosis reduces infarct size and improves regional contractile dysfunction during reperfusion. Cardiovasc Res 2003, 59:132-142.
14. Valen G. The basic biology of apoptosis and its implications for cardiac function and viability. Ann Thorac Surg 2003, 75:S656-S660.
15. Walker M.J., Curtis M.J., Hearse D.J., Campbell R.W., Janse M.J., Yellon D.M., Cobbe S.M., Coker S.J., Harness J.B., Harron D.W. The Lambeth conventions: guidelines for the study of arrhythmias in ischemia infarction, and reperfusion. Cardiovasc Res 1988, 22:447-455.
16. Saraste A., Pulkki K., Kallajoki M., Henriksen K., Parvinen M., Voipio-Pulkki L.M. Apoptosis in human acute myocardial infarction. Circulation 1997, 95:320-323.
17. Birnbaum Y., Hale S.L., Kloner R.A. Differences in reperfusion length following 30 minutes of ischemia in the rabbit influence infarct size, as measured by triphenyltetrazolium chloride staining. J Mol Cell Cardiol 1997, 29:657-666.
18. Ferrera R., Benhabbouche S., Bopassa J.C., Li B., Ovize M. One hour reperfusion is enough to assess function and infarct size with TTC staining in Langendorff rat model. Cardiovasc Drugs Ther 2009, 23:327-331.
19. Redel A., Jazbutyte V., Smul T.M., Lange M., Eckle T., Eltzschig H., Roewer N., Kehl F. Impact of ischemia and reperfusion times on myocardial infarct size in mice in vivo. Exp Biol Med 2008, 233:84-93.
20. Schwarz E.R., Somoano Y., Hale S.L., Kloner R.A. What is the required reperfusion period for assessment of myocardial infarct size using triphenyltetrazolium chloride staining in the rat?. J Thromb Thrombolysis 2000, 10:181-187.
21. Nakamura M., Wang N.P., Zhao Z.Q., Wilcox J.N., Thourani V., Guyton R.A., Vinten-Johansen J. Preconditioning decreases Bax expression, PMN accumulation and apoptosis in reperfused rat heart. Cardiovasc Res 2000, 45:661-670.
22. Chen Z., Chua C.C., Ho Y.S., Hamdy R.C., Chua B.H.L. Overexpression of Bcl-2 attenuates apoptosis and protects against myocardial I/R injury in transgenic mice. Am J Physiol Heart Circ Physiol 2001, 280:H2313-H2320.
23. Valen G., Yan Z.Q., Hansson G.K. Nuclear factor kappa-B and the heart. J Am Coll Cardiol 2001, 38:307-314.
24. Kabon B., Kurz A. Optimal perioperative oxygen administration. Curr Opin Aneasthesiol 2006, 19:11-18.
25. Tahepold P., Ruusalepp A., Li G., Vaage J., Starkopf J., Valen G. Cardioprotection by breathing hyperoxic gas-relation to oxygen concentration and exposure time in rats and mice. Eur J Cardiothorac Surg 2002, 21:987-994.